

Low estrogen has evolved to **No Estrogen!**



An estrogen-free drospirenone formulation did not exist until 2019.

ZERO IN ON Slynd[®] (drospirenone) tablets, 4mg

Estrogen-free Slynd offers a manageable bleeding profile with a flexible 24-hour missed pill window.¹ Low cardiovascular risk may also be associated with Slynd.²

Tablets must be taken every day at about the same time of the day so that the interval between two tablets is always 24 hours.¹


References: 1. Slynd[®] package insert; 2019. 2. Data on file.

Indications and usage

Slynd[®] is a progestin indicated for use by females of reproductive potential to prevent pregnancy.

Please see Slynd Important Safety Information on page 19 and full Prescribing information in pocket.

Slynd clinical studies included 39.2% of patients with 1 or 2 VTE risk factors:¹



Reference: 1. Data on file.

Contraindications

Slynd is contraindicated in females with renal impairment, adrenal insufficiency, a presence or history of cervical cancer or progestin sensitive cancers, liver tumors (benign or malignant) or hepatic impairment, and undiagnosed abnormal uterine bleeding.


Warnings and Precautions

Thromboembolic Disorders: Discontinue Slynd if a thromboembolic event occurs and consider discontinuing Slynd in case of prolonged immobilization due to surgery or illness. When prescribing Slynd, consider the increased risk of thromboembolism inherent in the postpartum period and in females with a history of thromboembolism.

Slynd[®]
(drospirenone) tablets, 4mg
An estrogen-free pill you can count on!

Slynd has a manageable bleeding profile...¹

In clinical studies, over 13 cycles:



- **Breakthrough bleeding** improved over time¹
- At cycle 12, **50.6%** of subjects reported **amenorrhea**^{2,a}
- **Discontinuation rate** due to bleeding irregularities was **3.5%** of total subjects^{1,b}

^a No bleeding or spotting days reported during entire exposure cycle.

^b 91/2593 (3.5% of total subjects)

References: 1. Slynd[®] package insert; 2019. 2. Data on file

Warnings and Precautions (cont'd)

Bleeding Irregularities and Amenorrhea: Females may experience irregular bleeding or amenorrhea, especially during the first three months of use. If bleeding persists, occurs after previously regular cycles, or if scheduled bleeding does not occur, evaluate for possible causes such as pregnancy or malignancy.

Discontinue Slynd if pregnancy occurs.

Counsel patients that Slynd does not protect against HIV-infection (AIDS) and other sexually transmitted infections.

Slynd[®]
(drospirenone) tablets, 4mg
An estrogen-free pill you can count on!

The active ingredient in Slynd is drospirenone

- Drospirenone features include **anti-androgenic** and **antimineralocorticoid** activity¹⁻³
 - Has no known androgenic activity⁴
 - Associated with increased sodium excretion²

	Anti-androgenic Activity ^{1-3,a}	Antimineralocorticoid Activity ^{1-3,a}
Drospirenone	+	+
Levonorgestrel	-	-
Norgestimate	-	-
Norethindrone	-	-

^aTable includes comparison of most commonly found progestones in the US oral contraceptive market. Progestational Activity: Levonorgestrel 5.3, Norgestimate 1.3, Norethindrone 1.0, Drospirenone 1.5. Progestational and androgenic activity are relative to 1 mg dose of norethindrone.

References: 1. Slynd® package insert. 2019. 2. Duijkers IJM, Heger-Mahn D, Drouin D, et al. Contraception. 2016;93(4): 303-309. 3. Batur B. Cleveland Clinic. Disease management: Female Contraception. December 2016. 4. Rice C, et al. US Pharm. 2006;6:62-70.

Warnings and Precautions

Hyperkalemia: Slynd has anti-mineralocorticoid activity, including the potential for hyperkalemia in high-risk females. Check serum potassium levels prior to starting treatment and during the first treatment cycle in females receiving daily, long-term treatment for chronic conditions or diseases with medications that may increase serum potassium concentration. Consider monitoring serum potassium concentration in females at increased risk for hyperkalemia i.e., those females who take a strong CYP3A4 inhibitor long-term and concomitantly with Slynd. Monitor females taking Slynd who later develop conditions and/or begin medication that put them at an increased risk for hyperkalemia.

Slynd[®]
(drospirenone) tablets, 4mg

An estrogen-free pill you can count on!

Slynd has a **flexible** 24-hour missed pill window to accommodate her busy life¹

This provides the margin she needs to be successful on Slynd

Norethindrone POPs^{2,a}



Slynd



- **30-hour elimination half-life** helps maintain therapeutic plasma levels.^{1,3}

Tablets must be taken every day at about the same time of the day so that the interval between two tablets is always 24 hours.³

^a Brand name Micronor

References: 1. Duijkers IJM, et al. Contraception. 2016;93(4): 303-309. 2. Micronor [package insert]. Janssen Pharmaceutical Companies; Titusville, NJ; 2021. 3. Slynd® package insert; 2019.

Warnings and Precautions (cont'd)

Bone Loss: Treatment with Slynd leads to decreased estradiol serum levels. It is unknown if this may cause a clinically relevant loss of bone mineral density.


Ectopic Pregnancy: Be alert to the possibility of ectopic pregnancy in females who become pregnant or complain of lower abdominal pain while on Slynd.

Risk of Hyperglycemia in Patients with Diabetes: Females with diabetes may be at greater risk of hyperglycemia and may require additional medication adjustments or monitoring. Progestins, including Slynd, may decrease insulin sensitivity.

Slynd[®]
(drospirenone) tablets, 4mg

An estrogen-free pill you can count on!

Slynd provides **effective** pregnancy prevention...^{1,a}



Primary Mechanism
of Action:

**OVULATION
SUPPRESSION¹**

98.2%

**AVOIDED PREGNANCY IN
CLINICAL STUDIES¹**
1.8% pregnancies

(17 out of 953 females evaluated)

4.0

PEARL INDEX¹
(95% CI; 2.3, 6.4)
out of 5547
evaluable cycles

Studies included

high BMI subjects:¹

mean BMI 28.5 kg/m²;

332 subjects BMI \geq 30 (35%) and

173 females had BMI \geq 35 (18%)



^a Efficacy and safety were assessed in an open-label, prospective, multicenter, non-controlled trial of 953 enrolled female subjects, aged 15 and above.

Reference: 1. Slynd® package insert; 2019.

Indications and Usage

Slynd (drospirenone) tablets are a progestin, indicated for females of reproductive potential to prevent pregnancy.

Contraindications

Slynd is contraindicated in females with renal impairment, adrenal insufficiency, a presence or history of cervical cancer or progestin sensitive cancers, liver tumors (benign or malignant) or hepatic impairment, and undiagnosed abnormal uterine bleeding.

Adverse Reactions


Most common adverse reactions (>1%) are: acne, metrorrhagia, headache, breast pain, weight increased, dysmenorrhea, nausea, vaginal hemorrhage, decreased libido, breast tenderness, irregular menstruation.

Slynd[®]
(drospirenone) tablets, 4mg

An estrogen-free pill you can count on!

Slynd has proven in clinical studies with over 20,000 cycles that it is a **safe** oral contraceptive...¹

and can be a more simple choice for your telemedicine patients than COCs and IUDs



Given its relatively safe profile and **no boxed warning**, Slynd **does not require a blood pressure check prior to initiation.**¹

^a Studies have not indicated an association between progestin-only preparations and an increased risk of myocardial infarction, cerebral thromboembolism, or venous thromboembolism.

References: 1. Data on file. 2. Slynd[®] package insert, 2019.

Contraindications

Slynd is contraindicated in females with renal impairment, adrenal insufficiency, a presence or history of cervical cancer or progestin sensitive cancers, liver tumors (benign or malignant) or hepatic impairment, and undiagnosed abnormal uterine bleeding.

Warnings and Precautions (cont'd)

Thromboembolic Disorders: Discontinue Slynd if a thromboembolic event occurs and consider discontinuing Slynd in case of prolonged immobilization due to surgery or illness. When prescribing Slynd, consider the increased risk of thromboembolism inherent in the postpartum period and in females with a history of thromboembolism.


Slynd[®]
(drospirenone) tablets, 4mg

An estrogen-free pill you can count on!

Slynd has a familiar **24+4 dosing** regimen that is similar to COCs¹

which provides a scheduled withdrawal bleed for which she can plan and anticipate.


Norethindrone POPs^{2,a}
28 pill dosing regimen
No placebo pills



^a Brand name Micronor

References: 1. Data on file. 2. Micronor [package insert]. Janssen Pharmaceutical Companies; Titusville, NJ; 2021. 3. Slynd® package insert; 2019.

Slynd
24+4 dosing regimen
24 active hormone pills + 4 placebo pills³



Warnings and Precautions (cont'd)

Bleeding Irregularities and Amenorrhea: Females may experience irregular bleeding or amenorrhea, especially during the first three months of use. If bleeding persists, occurs after previously regular cycles, or if scheduled bleeding does not occur, evaluate for possible causes such as pregnancy or malignancy.

Drug Interactions

Drugs or herbal products that induce certain enzymes (for example, CYP3A4) may decrease the effectiveness of Slynd or increase breakthrough bleeding. Counsel patients to use a back-up or alternative non-hormonal method of contraception when enzyme inducers are used with Slynd and to continue back-up non-hormonal contraception for 28 days after discontinuing the enzyme inducer. Drugs or products that inhibit CYP3A4 may increase Slynd systemic exposure.

Slynd[®]
(drospirenone) tablets, 4mg
An estrogen-free pill you can count on!

Prescribe Slynd via **telemedicine** with confidence!



No Boxed Warning!

- **No** Boxed Warning pertaining to female smokers 35 years and older¹



- **No** reported thromboembolic or CV events in clinical studies, which distinguishes drospirenone used alone versus in combination with estrogen in study²



- **No** blood pressure check required prior to initiation, making it a simpler choice for telemedicine²

References: 1. Slynd® package insert; 2019. 2. Data on file.



Warnings and Precautions (cont'd)

Thromboembolic Disorders: Discontinue Slynd if a thromboembolic event occurs and consider discontinuing Slynd in case of prolonged immobilization due to surgery or illness. When prescribing Slynd, consider the increased risk of thromboembolism inherent in the postpartum period and in females with a history of thromboembolism.

Contraindications

Slynd is contraindicated in females with renal impairment, adrenal insufficiency, a presence or history of cervical cancer or progestin sensitive cancers, liver tumors (benign or malignant) or hepatic impairment, and undiagnosed abnormal uterine bleeding.

Slynd
(drospirenone) tablets, 4mg

An estrogen-free pill you can count on!

IMPORTANT SAFETY INFORMATION

Indications and Usage

Slynd (drospirenone) tablets are a progestin, indicated for females of reproductive potential to prevent pregnancy.

Contraindications

Slynd is contraindicated in females with renal impairment, adrenal insufficiency, a presence or history of cervical cancer or progestin sensitive cancers, liver tumors (benign or malignant) or hepatic impairment, and undiagnosed abnormal uterine bleeding.

Warnings and Precautions

Hyperkalemia: Slynd has anti-mineralocorticoid activity, including the potential for hyperkalemia in high-risk females. Check serum potassium levels prior to starting treatment and during the first treatment cycle in females receiving daily, long-term treatment for chronic conditions or diseases with medications that may increase serum potassium concentration. Consider monitoring serum potassium concentration in females at increased risk for hyperkalemia i.e., those females who take a strong CYP3A4 inhibitor long-term and concomitantly with Slynd. Monitor females taking Slynd who later develop conditions and/or begin medication that put them at an increased risk for hyperkalemia.

Thromboembolic Disorders: Discontinue Slynd if a thromboembolic event occurs and consider discontinuing Slynd in case of prolonged immobilization due to surgery or illness. When prescribing Slynd, consider the increased risk of thromboembolism inherent in the postpartum period and in females with a history of thromboembolism.

Bone Loss: Treatment with Slynd leads to decreased estradiol serum levels. It is unknown if this may cause a clinically relevant loss of bone mineral density.

Ectopic Pregnancy: Be alert to the possibility of ectopic pregnancy in females who become pregnant or complain of lower abdominal pain while on Slynd.

Risk of Hyperglycemia in Patients with Diabetes: Females with diabetes may be at greater risk of hyperglycemia and may require additional medication adjustments or monitoring. Progestins, including Slynd, may decrease insulin sensitivity.

Bleeding Irregularities and Amenorrhea: Females may experience irregular bleeding or amenorrhea, especially during the first three months of use. If bleeding persists, occurs after previously regular cycles, or if scheduled bleeding does not occur, evaluate for possible causes such as pregnancy or malignancy.

Adverse Reactions

Most common adverse reactions (>1%) are: acne, metrorrhagia, headache, breast pain, weight increased, dysmenorrhea, nausea, vaginal hemorrhage, decreased libido, breast tenderness, irregular menstruation.

To report SUSPECTED ADVERSE REACTIONS, contact Exeltis USA, Inc. at 1-877-324-9349 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Drug Interactions

Drugs or herbal products that induce certain enzymes (for example, CYP3A4) may decrease the effectiveness of Slynd or increase breakthrough bleeding. Counsel patients to use a back-up or alternative non-hormonal method of contraception when enzyme inducers are used with Slynd and to continue back-up non-hormonal contraception for 28 days after discontinuing the enzyme inducer. Drugs or products that inhibit CYP3A4 may increase Slynd systemic exposure.

Discontinue Slynd if pregnancy occurs.

Counsel patients that Slynd does not protect against HIV-infection (AIDS) and other sexually transmitted infections.

ZERO IN ON Slynd[®]

(drospirenone) tablets, 4mg

Count on estrogen-free Slynd for more of your patients¹

	Women who prefer to avoid unnecessary hormones ¹	Breastfeeding (FDA approved) ¹	High BMI (≥30) ¹	Smokers + CV Risk (No boxed warning) ¹	12-18 years old (FDA approved) ¹
Slynd [®]	✓	✓	✓	✓	✓
COMBINED OC	✗	✗	?	✗	?

SLYND SAVINGS PROGRAM

Patients may be eligible for savings on one or three month prescription fills of SLYND

ELIGIBLE PATIENTS MAY
PAY AS LITTLE AS

\$25 PER **1-MONTH**
OR **3-MONTH**
PRESCRIPTION FILL^a

3 MONTH FILL MAY COST PATIENT
\$8.33 PER MONTH

ELIGIBLE PATIENTS MAY
ALSO ACCESS SAVINGS
ONLINE OR VIA **TEXT**^b



Visit
SLYND.COM



Text
SLYND to 31700

^a Maximum savings limits apply; patient out-of-pocket expense will vary depending on insurance coverage. Offer not valid for patients enrolled in Medicare, Medicaid, or other federal or state healthcare programs. Additional program terms, conditions, and eligibility criteria apply. Visit [Slynd.com](https://slynd.com) for details.

^b Text SLYND to 31700 to receive your Exeltis Women's Health Savings Card. Message and data rates may apply. Message frequency varies. Text STOP to opt out. Text HELP for help. For Privacy Policy: <https://exeltisusa.com/privacy-policy/>. For SMS Terms: <https://exeltis.online/SMStext>.

To report **SUSPECTED ADVERSE REACTIONS**, contact Exeltis USA, Inc. at 1-877-324-9349 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Reference: 1. Slynd[®] package insert; 2019.

Please see Slynd Important Safety Information on previous page and full Prescribing information in pocket.

Slynd[®] is a registered trademark of Chemo Research, S.L. ©2023 Exeltis USA, Inc. All rights reserved. EXS-22-011 R01

